Notes

Plectin throughout Skin Frailty Problems.
This study aims to identify the prognosis of the extracapsular spread (ECS) of cervical lymph node metastases in nasopharyngeal carcinoma (NPC).

Patients with NPC were extracted from the Surveillance, Epidemiology, and End Results (SEER) database from 2004 to 2016. Pathologically confirmed World Health Patients with World Health Organization types I, II, and III NPC with complete ECS data of cervical lymph node metastases were investigated. The included patients were divided into non-ECS and ECS groups. The 10-year overall survival (OS) and cancer-specific survival (CSS) were compared between the two groups using the Kaplan-Meier method and propensity score matching analyses.

A total of 625 patients were included. The ECS group included 99 (15.84%) patients. The non-ECS group included 526 (84.16%) patients. The 10-year OS (50.2 vs. 35.8%;
< 0.001) and CSS (64.8 vs. 45.7%;
< 0.001) were better in the non-ECS group than in the ECS group in the unmatched cohort. Propensity score matching analyses revealed favorable 10-year OS (52.7 vs. 35.8%;
= 0.008) and CSS (61.2 vs. 45.7%;
= 0.008) in the non-ECS group with respect to the ECS group. Age, sex, race, AJCC stage, and ECS (hazard ratio (HR) = 1.71, 95% confidence interval (CI), 1.14-2.57,
= 0.010) were independent prognostic factors for OS. Age, sex, AJCC stage, and ECS (HR = 1.91; 95% CI, 1.21-3.01;
= 0.005) were independent prognostic factors for CSS.

This study indicated that ECS is a prognostic risk factor for NPC. Further studies should be performed to verify the results due to the limitations of the SEER database.
This study indicated that ECS is a prognostic risk factor for NPC. Further studies should be performed to verify the results due to the limitations of the SEER database.Cancer cachexia is a multifactorial syndrome characterized by continuous body wasting and loss of skeletal muscle. Impaired mitochondria function is closely associated with muscle atrophy in cancer cachexia. Our previous study confirmed the effectiveness of Baoyuan Jiedu decoction (BJD) in inhibiting cancer-induced muscle atrophy in an in vivo model. However, little is known about its mechanisms in regulating mitochondria dysfunction. In this study, we evaluated the therapeutic effect and action mechanisms of BJD against atrophy both in the Lewis-conditioned medium induced C2C12 myotube atrophy model and in a BALB/c mice xenograft model using mouse colon cancer C26 cells. The mitochondrial content was tested by 10-Non-ylacridine orange staining. Expressions of related proteins and mRNAs were detected by western blotting (WB) and qPCR, respectively. As a result, 18 major components were identified in BJD by ultra-high performance liquid chromatography-quadrupole (UHPLC-Q) Exactive analysis. As shown in the in myotube atrophy and provided a potential mechanism for BJD in regulating mitochondrial dynamics through p38 MAPK/PGC-1α signaling pathway.Ovarian cancer is the most lethal gynecologic malignancy. Early detection would improve survival, but an effective diagnostic test does not exist. Novel biomarkers for early ovarian cancer diagnosis are therefore warranted. We performed intraoperative blood sampling from ovarian veins of stage I epithelial ovarian carcinomas and analyzed the serum proteome. Junction plakoglobin (JUP) was found to be elevated in venous blood from ovaries with malignancies when compared to those with benign disease. Peripheral plasma JUP levels were validated by ELISA in a multicenter international patient cohort. JUP was significantly increased in FIGO serous stage IA+B (1.97-fold increase; p less then 0.001; n = 20), serous stage I (2.09-fold increase; p less then 0.0001; n = 40), serous stage II (1.81-fold increase, p less then 0.001, n = 23) and serous stage III ovarian carcinomas (1.98-fold increase; p less then 0.0001; n = 34) vs. normal controls (n = 109). JUP plasma levels were not increased in early stage breast cancer (p = 0.122; n = 12). In serous ovarian cancer patients, JUP had a sensitivity of 85% in stage IA+B and 60% in stage IA-C, with specificities of 76 and 94%, respectively. A logistic regression model of JUP and Cancer Antigen 125 (CA125) revealed a sensitivity of 70% for stage IA+B and 75% for stage IA-C serous carcinomas at 100% specificity. read more Our novel ovarian blood sampling - proteomics approach identified JUP as a promising new biomarker for epithelial ovarian cancer, which in combination with CA125 might fulfill the test criteria for ovarian cancer screening.Purpose To analyze geometric discrepancy and dosimetric impact in using contours generated by auto-segmentation (AS) against manually segmented (MS) clinical contours. Methods A 48-subject prostate atlas was created and another 15 patients were used for testing. Contours were generated using a commercial atlas-based segmentation tool and compared to their clinical MS counterparts. The geometric correlation was evaluated using the Dice similarity coefficient (DSC) and Hausdorff distance (HD). Dosimetric relevance was evaluated for a subset of patients by assessing the DVH differences derived by optimizing plan dose using the AS and MS contours, respectively, and evaluating with respect to each. A paired t-test was employed for statistical comparison. The discrepancy in plan quality with respect to clinical dosimetric endpoints was evaluated. The analysis was repeated for head/neck (HN) with a 31-subject atlas and 15 test cases. Results Dice agreement between AS and MS differed significantly across structures from (L0.92/R 0.91) for the femoral heads to seminal vesical of 0.38 in the prostate cohort, and from 0.98 for the brain, to 0.36 for the chiasm of the HN group. Despite the geometric disagreement, the paired t-tests showed the lack of statistical evidence for systematic differences in dosimetric plan quality yielded by the AS and MS approach for the prostate cohort. In HN cases, statistically significant differences in dosimetric endpoints were observed in structures with small volumes or elongated shapes such as cord (p = 0.01) and esophagus (p = 0.04). The largest absolute dose difference of 11 Gy was seen in the mean pharynx dose. Conclusion Varying AS performance among structures suggests a differential approach of using AS on a subset of structures and focus MS on the rest. The discrepancy between geometric and dosimetric-end-point driven evaluation also indicates the clinical utility of AS contours in optimization and evaluating plan quality despite of suboptimal geometrical accuracy.
Homepage: https://www.selleckchem.com/products/Fulvestrant.html